Top

Published in:

01-04-2018 | Original Article

Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate

Authors: Huan Xu, Zhikang Cai, Yanbo Chen, Meng Gu, Qi Chen, Zhong Wang

Published in: Lasers in Medical Science | Issue 3/2018

Abstract

To develop a standardized scoring system, the BPH surgical scoring (BPHSS) system, to quantify the ability to predict the perioperative outcomes resulting from an enlarged prostate. There are two parts included in this study: the retrospective observational study (875 patients treated with holmium laser enucleation of the prostate, HoLEP) and the prospective observational study (111 patient underwent HoLEP). All the outcome data included the following: the basic patient preoperative characteristics, operation time (OT), pre- and post- surgery hemoglobin decrease, Na⁺ variation, hospital stay duration, duration of bladder irrigation, catheterization time, and hospitalization time. The BPHSS, consisting of prostatic volume (PV), prostate-specific antigen (PSA), bladder stones, intravesical prostatic protrusion (IPP), and metabolic syndrome (MetS), was observed regarding the perioperative outcomes. In the retrospective study, patients in high BPHSS group (6–8 points) showed significant increase in the OT (74.61, 95%CI = 16.98–327.84, P < 0.001), hemochrome reduction (416.50, 95%CI = 35.48–4889.88, P < 0.001), hospital stay (1.80, 95%CI = 1.35–2.41, P < 0.001), and bladder irrigation duration (4.04, 95%CI = 1.35–12.10, P = 0.013) compared with the low BPHSS group (0–2 points). In the prospective study, there also existed significant differences between the three scoring grades (P < 0.01) in OT, hemochrome decrease, and the hospital stay. The BPHSS is suitable to predict the perioperative outcomes in patients undergoing HoLEP. It may help urologist to prepare more before surgery to treat the enlarged prostates. Further studies are needed to validate this scoring system in BPH patients in multiple centers.

Available only for authorised users

Oelke M et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140CrossRefPubMed

Kahokehr A, Gilling PJ (2014) Enucleation techniques for benign prostate obstruction: which one and why? Curr Opin Urol 24(1):49–55CrossRefPubMed

Rieken M, Bachmann A (2014) Laser treatment of benign prostate enlargement--which laser for which prostate? Nat Rev Urol 11(3):142–152CrossRefPubMed

Zhang X et al (2016) Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis. Sci Rep 6:23503CrossRefPubMedPubMedCentral

Grundy SM et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752CrossRefPubMed

Chen YB et al (2013) A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol 189(1):217–222CrossRefPubMed

van Rij S, Gilling PJ (2012) In 2013, holmium laser enucleation of the prostate (HoLEP) may be the new 'gold standard'. Curr Urol Rep 13(6):427–432CrossRefPubMed

Tan AH, Gilling PJ (2003) Holmium laser prostatectomy. BJU Int 92(6):527–530CrossRefPubMed

Geavlete B et al (2013) Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases—a medium term, prospective, randomized comparison. BJU Int 111(5):793–803CrossRefPubMed

10.

Elzayat EA, Habib EI, Elhilali MM (2005) Holmium laser enucleation of the prostate: a size-independent new “gold standard”. Urology 66(5 Suppl):108–113CrossRefPubMed

11.

Busetto GM et al (2015) Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int 116(1):117–123CrossRefPubMed

12.

Netsch C et al (2012) Thulium:YAG vapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-microm lasers. Asian J Androl 14(2):325–329CrossRefPubMedPubMedCentral

13.

Lee DJ et al (2016) Laser vaporization of the prostate with the 180-W XPS-greenlight laser in patients with ongoing platelet aggregation inhibition and oral anticoagulation. Urology 91:167–173CrossRefPubMed

14.

Gilling P, Anderson P, Tan A (2017) Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol 197(6):1565–1572

15.

Keehn A et al (2017) UroLift in place of fiducial markers for patients with benign prostatic hyperplasia undergoing external beam radiation therapy. Urology 104:230–234CrossRefPubMed

16.

Jeong CW et al (2010) Minimally invasive management of postoperative bleeding after radical prostatectomy: transarterial embolization. J Endourol 24(9):1529–1533CrossRefPubMed

17.

Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 53(1):160–166CrossRefPubMed

18.

Monn MF et al (2015) Predictors of enucleation and morcellation time during holmium laser enucleation of the prostate. Urology 86(2):338–342CrossRefPubMed

19.

Hirayama K et al (2015) Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology 86(3):565–569CrossRefPubMed

20.

Lee JY et al (2012) Single-port transvesical enucleation of the prostate for benign prostatic hyperplasia with severe intravesical prostatic protrusion. World J Urol 30(4):511–517CrossRefPubMed

21.

Marks LS, Roehrborn CG, Andriole GL (2006) Prevention of benign prostatic hyperplasia disease. J Urol 176(4 Pt 1):1299–1306CrossRefPubMed

22.

Roehrborn CG et al (2001) Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58(2):210–216CrossRefPubMed

23.

Roehrborn CG et al (1999) Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53(3):581–589CrossRefPubMed

24.

Ma D et al (2014) Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining. Chin Med J 127(23):4031–4035PubMed

25.

Choo MS et al (2014) Transurethral surgical anatomy of the arterial bleeder in the enucleated capsular plane of enlarged prostates during holmium laser enucleation of the prostate. Int Neurourol J 18(3):138–144CrossRefPubMedPubMedCentral

26.

Roehrborn CG (2004) The clinical benefits of dutasteride treatment for LUTS and BPH. Rev Urol 6(Suppl 9):S22–S30PubMedPubMedCentral

27.

Ozden C et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–203 discussion 204-6CrossRefPubMed

28.

Muller RL et al (2013) Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 63(6):1115–1121CrossRefPubMed

29.

De Nunzio C et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570CrossRefPubMed

30.

Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119CrossRefPubMed

31.

Xu H et al (2017) Oxytocin: its role in benign prostatic hyperplasia via the ERK pathway. Clin Sci (Lond) 131(7):595–607

32.

Kasturi S, Russell S, McVary KT (2006) Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 7(4):288–292CrossRefPubMed

33.

Miller DC, Park JM (2003) Percutaneous cystolithotomy using a laparoscopic entrapment sac. Urology 62(2):333–336 discussion 336CrossRefPubMed

Title: Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate
Authors: Huan Xu
Zhikang Cai
Yanbo Chen
Meng Gu
Qi Chen
Zhong Wang
Publication date: 01-04-2018
Publisher: Springer London
Published in: Lasers in Medical Science / Issue 3/2018
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-017-2425-1

At a glance: The STEP trials

Springer Medicine

Benign prostatic hyperplasia surgical scoring (BPHSS): an novel scoring system for the perioperative outcomes of holmium laser enucleation of the prostate

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Laser for bone healing after oral surgery: systematic review

EMLA cream does not influence efficacy and pain reduction during pulsed-dye laser treatment of port-wine stain: a prospective side-by-side comparison

Anti-inflammatory effects of low-level laser therapy on human periodontal ligament cells: in vitro study

Potential role of S100A8 in skin rejuvenation with the 1064-nm Q-switched Nd:YAG laser

Chondroitin sulfate and glucosamine sulfate associated to photobiomodulation prevents degenerative morphological changes in an experimental model of osteoarthritis in rats

Activation of Wnt/β-catenin signaling is involved in hair growth-promoting effect of 655-nm red light and LED in in vitro culture model